Physician profile
Eugene A Cullen
NPI 1487620407
$4,703.05
in general payments reported to CMS, 2019-2025
36 companies · $647 in 2025
The $647 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $58.57 · 2021: $214 · 2022: $636 · 2023: $1,077 · 2024: $999 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,722.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,045.12 | 2021-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $587.45 | 2019-2025 | |
| Amgen INC. | $346.83 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $292.45 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $291.79 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $281.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $261.47 | 2023-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $188.40 | 2019-2023 | Dificid, Belsomra, Steglatro |
| Allergan, INC. | $160.59 | 2019 | |
| Lilly USA, LLC | $132.87 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Kowa Pharmaceuticals America, INC. | $123.96 | 2019-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.73 | 2019-2025 | Jardiance |
| Comsort, INC | $100.00 | 2019 | |
| Amarin Pharma, INC. | $88.72 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $63.25 | 2019-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Cullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.